PRGO · PERRIGO COMPANY PLC

Current Thesis

Perrigo’s turnaround thesis rests on asset sales reducing debt while earnings guidance survives; a completed strategic transaction and subsequent results would test that case, while a weekly close below $13.00 would invalidate the price-supported recovery thesis. The 2026-08-05 results release reported adjusted diluted earnings per share (EPS) of $0.50 and reaffirmed full-year core adjusted EPS guidance of $2.25–$2.55. Infant Formula and Oral Care remained under strategic review at that date.

The September refresh weakens the acceleration argument. The market’s adjusted close was $13.66 on 2026-09-11, and the 14-day relative strength index (RSI) was 45.3. As an inference from that momentum reading and the elapsed conference window, the narrative is maturing — the 2026-09-10 Barclays meetings are past, while the company’s investor page still listed its 2026-08-27 conference announcement as its latest release when checked on 2026-09-13. That supports a lower-confidence continuation case; a disclosed strategic agreement accompanied by renewed price strength would overturn the maturation assessment. Perrigo investor relations

Bullish and bearish views on PERRIGO COMPANY PLC

The model's bull view on PERRIGO COMPANY PLC (PRGO), in brief: Earnings guidance survived declining sales. The bear view: Demand recovery remains unproven. Second-quarter 2026 core organic sales fell 3.5%, and the 2026-08-05 full-year core organic sales guidance ranged from a 3.0% decline to 1.0% growth. The published range still allowed contraction. Debt exceeds available cash substantially.… Both cases follow in full.

Bull Case

• Earnings guidance survived declining sales. Perrigo reaffirmed core adjusted EPS guidance of $2.25–$2.55 on 2026-08-05 despite second-quarter core net sales falling 3.1% year over year. This supports an earnings-stabilisation interpretation, which a subsequent reduction below the $2.25 lower bound would invalidate.
• Asset disposal already reduced debt. The 2026-08-05 results release reported approximately $359 million of Dermacosmetics disposal proceeds, substantially applied to debt reduction. This establishes a completed example of the portfolio strategy; an announcement ending the remaining reviews without transactions would invalidate the extension of that mechanism to Infant Formula and Oral Care.
• Quarterly cash generation was positive. Operating cash flow reached $83 million in the second quarter of 2026, according to the 2026-08-05 release. The first-half total remained negative $31 million, so the quarterly improvement alone does not establish a sustained recovery.

Bear Case

• Demand recovery remains unproven. Second-quarter 2026 core organic sales fell 3.5%, and the 2026-08-05 full-year core organic sales guidance ranged from a 3.0% decline to 1.0% growth. The published range still allowed contraction.
• Debt exceeds available cash substantially. Perrigo reported $3.3 billion of total debt and $400 million of cash in its 2026-08-05 results release. The completed Dermacosmetics disposal therefore establishes progress without establishing that the balance-sheet problem is resolved.
• Conference confirmation is missing. The 2026-08-27 announcement scheduled investor meetings for 2026-09-10; it did not promise transaction news or revised guidance. The investor page checked on 2026-09-13 supplied no subsequent release confirming either outcome. The earlier conference-dependent acceleration case has therefore reached its deadline without verifiable confirmation, although this does not establish what was discussed privately. Conference announcement, company releases and events

Setup & Price Structure

The supplied adjusted market series records a $13.66 close on 2026-09-11, a three-month price increase of 26.2%, and a price 35.2% below its 52-week high of $21.08. Those measurements describe a recovery within a larger decline. The previously published $13.00 weekly-close threshold remains the research invalidation level; the September 11 close had not breached it. The supplied bars do not independently establish the earlier description of that threshold as the exact earnings-gap boundary.

The 2026-09-11 RSI reading of 45.3 provides no evidence of stretched upward momentum. Moving-average levels, short interest and a comparable volume series are missing, so distance above a rising average and the breadth of participation cannot be assessed.

Retail-facing attention extends beyond the supplied 2026-08-25 Benzinga dividend screen: Zacks published an earnings-follow-up article on 2026-09-04. These observations are too sparse to support a crowding claim. Perrigo’s filing index also lists a Form 4 dated 2026-09-10, but the index alone does not establish insider selling or its motivation. Zacks article, Perrigo filing index

Catalyst Calendar (next 30 days)

• 2026-09-13 through 2026-10-13: No company-confirmed catalyst within this window was identified on the investor page checked on 2026-09-13. The next quarterly reporting date remains unconfirmed in the reviewed company material. Perrigo investor relations

The Infant Formula and Oral Care reviews were continuing on 2026-08-05, but no resolution date was supplied. An unscheduled agreement would test whether another disposal can reduce debt; assigning it a calendar date would imply information that is unavailable.

What Would Change Our Mind

Loss of the retained recovery threshold would end the price-supported case: a weekly close below $13.00 is the observable break. Separately, a reduction in full-year core adjusted EPS guidance below the $2.25 lower bound reaffirmed on 2026-08-05 would invalidate the earnings-stabilisation component.

Positive confirmation requires an announced Infant Formula or Oral Care transaction with disclosed debt-reduction proceeds, together with subsequent results preserving the 2026-08-05 core EPS range. Those are conditions for confirmation, not assumed outcomes. Evidence confidence is low because the September 10 confirmation window has elapsed and the September 11 market close remains above, but near, the retained invalidation threshold.

Correlation Notes

This remains a single-company turnaround case. The 2026-08-05 evidence concerns Perrigo’s own declining core sales, disposal proceeds and debt; it does not establish participation in a wider rotation. The supplied 2026-09-11 price observations contain no comparable sector or index return series, so no measured correlation can be stated. The 2026-08-25 Benzinga article’s grouping of Perrigo with Pfizer and Bristol Myers Squibb establishes shared dividend-screen coverage, not shared operating drivers.